Patents by Inventor Jeffrey A. Kern
Jeffrey A. Kern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230099074Abstract: Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.Type: ApplicationFiled: October 26, 2022Publication date: March 30, 2023Applicants: Merck Sharp & Dohme LLC, Ambrx, Inc.Inventors: Philip E. Brandish, Robert M. Garbaccio, Jeffrey Kern, Linda Liang, Sanjiv Shah, Dennis Zaller, Andrew Beck, Dennis Gately, Nick Knudsen, Anthony Manibusan, Jianing Wang, Ying Sun
-
Patent number: 11510993Abstract: Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.Type: GrantFiled: September 30, 2016Date of Patent: November 29, 2022Assignees: Merck Sharp & Dohme LLC, Ambrx, Inc.Inventors: Philip E. Brandish, Robert M. Garbaccio, Jeffrey Kern, Linda Liang, Sanjiv Shah, Dennis Zaller, Andrew Beck, Dennis Gately, Nick Knudsen, Anthony Manibusan, Jianing Wang, Ying Sun
-
Patent number: 11186652Abstract: A method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells is provided, said method comprising a step of extracting LPS from the gram negative bacterial cell in a LPS extraction solution comprising a salt, water, an alcohol, and a further organic solvent. Compositions and uses of the extracted LPS are also provided.Type: GrantFiled: December 21, 2016Date of Patent: November 30, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Jeffrey A. Kern, Chad Farrenburg
-
Publication number: 20200164085Abstract: Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.Type: ApplicationFiled: September 30, 2016Publication date: May 28, 2020Inventors: Philip E. Brandish, Robert M Garbaccio, Jeffrey Kern, Linda Liang, Sanjiv Shah, Dennis Zaller, Andrew Beck, Dennis Gately, Nick Knudsen, Anthony Manibusan, Jianing Wang, Ying Sun
-
Publication number: 20200102405Abstract: A method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells is provided, said method comprising a step of extracting LPS from the gram negative bacterial cell in a LPS extraction solution comprising a salt, water, an alcohol, and a further organic solvent. Compositions and uses of the extracted LPS are also provided.Type: ApplicationFiled: December 21, 2016Publication date: April 2, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Jeffrey A. KERN, Chad FARRENBURG
-
Patent number: 10550190Abstract: Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).Type: GrantFiled: March 30, 2015Date of Patent: February 4, 2020Assignees: Merck Sharp & Dohme Corp., Ambrx, Inc.Inventors: Robert M. Garbaccio, Jeffrey Kern, Philip E. Brandish, Sanjiv Shah, Linda Liang, Ying Sun, Jianing Wang, Nick Knudsen, Andrew Beck, Anthony Manibusan, Dennis Gately
-
Publication number: 20170182181Abstract: Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).Type: ApplicationFiled: March 30, 2015Publication date: June 29, 2017Applicants: Merck Sharp & Dohme Corp., Ambrx, Inc.Inventors: Robert M. Garbaccio, Jeffrey Kern, Philip E. Brandish, Sanjiv Shah, Linda Liang, Ying Sun, Jianing Wang, Nick Knudsen, Andrew Beck, Anthony Manibusan, Dennis Gately
-
Patent number: 9206995Abstract: A duct adapter system directs air flow relative to a hybrid water heater. The duct adapter system includes a collar adapted to surround a vent of a hybrid water shroud. The collar couples to standard duct pipe to extend ductwork to a heat pump portion of the hybrid water heater. A boost fan may be included in the system for boosting air flow to or from a remote location. The duct adapter system is adapted to deliver a warm air supply to the heat pump from the remote location, or deliver the cool discharge air from the heat pump water heater to a remote location.Type: GrantFiled: July 7, 2011Date of Patent: December 8, 2015Assignee: General Electric CompanyInventors: Jonathan D. Nelson, Michael Thomas Beyerle, Jeffrey A. Kern, Eliel Fresco Rodriguez
-
Patent number: 9062059Abstract: The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: August 20, 2012Date of Patent: June 23, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher D. Cox, Vadim Y. Dudkin, Jeffrey Kern, Mark E. Layton, Izzat T. Raheem
-
Publication number: 20140228368Abstract: The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: ApplicationFiled: August 20, 2012Publication date: August 14, 2014Inventors: Christopher D. Cox, Vadim Y. Dudkin, Jeffrey Kern, Mark E. Layton, Izzat T. Raheem
-
Publication number: 20140121213Abstract: In general, the present invention relates to uses of voltage-gated sodium channel blocker compounds, which include corresponding precursors, intermediates, monomers and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory and respiratory tract diseases. In particular, the present invention also relates to methods and uses for treatment of respiratory or respiratory tract diseases, which comprises administering to a subject in need thereof an effective amount of a compound of the present invention.Type: ApplicationFiled: July 3, 2012Publication date: May 1, 2014Inventors: Jeffrey Charles Boehm, Roderick S. Davis, Jeffrey Kerns, Guoliang Lin, Robert D. Murdoch, Hong NIE
-
Publication number: 20120023990Abstract: A duct adapter system directs air flow relative to a hybrid water heater. The duct adapter system includes a collar adapted to surround a vent of a hybrid water shroud. The collar couples to standard duct pipe to extend ductwork to a heat pump portion of the hybrid water heater. A boost fan may be included in the system for boosting air flow to or from a remote location. The duct adapter system is adapted to deliver a warm air supply to the heat pump from the remote location, or deliver the cool discharge air from the heat pump water heater to a remote location.Type: ApplicationFiled: July 7, 2011Publication date: February 2, 2012Inventors: Jonathan D. Nelson, Michael Thomas Beyerle, Jeffrey A. Kern, Eliel Fresco Rodriguez
-
Publication number: 20090235674Abstract: This disclosure is related to software that responds to consumer usage patterns in order to create more ice. The developed software monitors ice dispenses rather they are crushed or cubed. When a threshold of the number of dispenses within the preset time period has been met, the freezer enters a high demand mode. During high demand mode, the freezer is commanded to run at a colder temperature for a preset period of time. The method described in this disclosure includes setting a threshold for the number of dispenses within a time interval and detecting the number of dispenses that are related to a trigger's activation. The method continues with sending a signal when the number of dispenses surpasses the threshold within the time interval and taking a corrective action that increases the production of ice when the signal is received.Type: ApplicationFiled: March 19, 2008Publication date: September 24, 2009Inventors: Jeffrey Kern, Richard DeVos, William Newton
-
Publication number: 20080119537Abstract: Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III.Type: ApplicationFiled: November 16, 2007Publication date: May 22, 2008Applicant: WyethInventors: Puwen Zhang, Jeffrey Kern, Eugene Terefenko, Eugene Trybulski
-
6-amino-1,4-dihydro-benzo[][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators
Patent number: 7354915Abstract: Compounds having the structure of formula I are provided. In formula I, R1 is H, OH, substituted or unsubstituted C1 to C3 alkyl, C1 to C3 perfluoroalkyl, or COR6; R6 is H, substituted or unsubstituted C1 to C4 alkyl, aryl, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted C1 to C3 aminoalkyl; R2 and R3 are H, substituted or unsubstituted C1 to C6 alkyl, C1 to C6 perfluoroalkyl, substituted or unsubstituted C2 to C6 alkenyl, substituted or unsubstituted C2 to C6 alkynyl, substituted or unsubstituted C3 to C6 cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclic; or R2 and R3 are fused to form spirocyclic rings; R4 is NHR7, OR7, NHSO2R7, or OSO2R7; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt, ester, or prodrug thereof.Type: GrantFiled: May 21, 2007Date of Patent: April 8, 2008Assignee: WyethInventors: Puwen Zhang, Jeffrey Kern -
Publication number: 20070281933Abstract: The invention is directed to novel indazole carboxamide derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 and Z are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: June 24, 2005Publication date: December 6, 2007Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Jeffrey Kerns, Christine Edwards
-
Publication number: 20070254873Abstract: The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: September 21, 2005Publication date: November 1, 2007Applicant: Glaxo Group LimitedInventors: Jeffrey Kerns, Michael Lindenmuth, Xichen Lin, Hong Nie, Sonia Thomas
-
Publication number: 20070225281Abstract: Compounds having the structure of formula I are provided. In formula I, R1 is H, OH, substituted or unsubstituted C1 to C3 alkyl, C1 to C3 perfluoroalkyl, or COR6; R6 is H, substituted or unsubstituted C1 to C4 alkyl, aryl, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted C1 to C3 aminoalkyl; R2 and R3 are H, substituted or unsubstituted C1 to C6 alkyl, C1 to C6 perfluoroalkyl, substituted or unsubstituted C2 to C6 alkenyl, substituted or unsubstituted C2 to C6 alkynyl, substituted or unsubstituted C3 to C6 cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclic; or R2 and R3 are fused to form spirocyclic rings; R4 is NHR7, OR7, NHSO2R7, or OSO2R7; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt, ester, or prodrug thereof. Such compounds are useful as progesterone receptor modulators and for treating progesterone receptor related conditions.Type: ApplicationFiled: May 21, 2007Publication date: September 27, 2007Applicant: WyethInventors: Puwen Zhang, Jeffrey Kern
-
Publication number: 20070208584Abstract: A method of providing greeting cards, the method comprises: providing, over a communication network, a list of potential recipients of a greeting card to multiple potential senders; receiving, from multiple potential senders, selection indication representative of one or more selected recipients and greeting information associated with the selection; generating, for each selected recipient, a greeting card that comprises the greeting information associated with the selected recipient.Type: ApplicationFiled: March 6, 2006Publication date: September 6, 2007Inventors: Jeffrey Kern, Aviv Aviad
-
Patent number: 7247625Abstract: Compounds having the structure of formula I are provided. In formula I, R1 is H, OH, substituted or unsubstituted C1 to C3 alkyl, C1 to C3 perfluoroalkyl, or COR6; R6 is H, substituted or unsubstituted C1 to C4 alkyl, aryl, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted C1 to C3 aminoalkyl; R2 and R3 are H, substituted or unsubstituted C1 to C6 alkyl, C1 to C6 perfluoroalkyl, substituted or unsubstituted C2 to C6 alkenyl, substituted or unsubstituted C2 to C6 alkynyl, substituted or unsubstituted C3 to C6 cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclic; or R2 and R3 are fused to form spirocyclic rings; R4 is NHR7, OR7, NHSO2R7, or OSO2R7; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt, ester, or prodrug thereof. Such compounds are useful as progesterone receptor modulators and for treating progesterone receptor related conditions.Type: GrantFiled: September 21, 2004Date of Patent: July 24, 2007Assignee: WyethInventors: Puwen Zhang, Jeffrey Kern